Repeated intracerebroventricular administration of glucagon-like peptide-1-736 amide or exendin939 alters body weight in the rat
AOD-9604 suppresses lipogenesis, the production of new fat stores, and increases lipolysis, the breakdown of fat, by mimicking the activity of endogenous hGH in adipose tissue
Although GLP-1RAs can reduce body weight by 15%25% in controlled settings, real-world adherence is limited, and nearly 70% of patients experience weight regain after discontinuation, raising the risk of long-term pharmacological dependence ( Looking ahead, the future of GLP-1based therapy will depend on addressing safety concerns, improving long-term adherence, and expanding clinical indications
The longer you have T1D, the greater your risk for complications including heart and kidney disease nerve damage, and vision problems